Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - azacitidin - pulver til injektionsvæske, suspension - 25 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm generics a/s - ranitidinhydrochlorid - filmovertrukne tabletter - 300 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - ranitidinhydrochlorid - filmovertrukne tabletter - 300 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

glaxosmithkline pharma a/s - ranitidinhydrochlorid - brusetabletter - 150 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

glaxosmithkline pharma a/s - ranitidinhydrochlorid - brusetabletter - 300 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

glaxosmithkline pharma a/s - ranitidinhydrochlorid - filmovertrukne tabletter - 150 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leukæmi, lymfocytisk, kronisk, b-celle - antineoplastiske midler - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

teva gmbh - risperidon - pulver og solvens til depotinjektionsvæske, suspension - 25 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukæmi, myeloid - antineoplastiske midler - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.